Enhanced Recovery After Surgery (ERAS) for gynaecologic cancer operations
Enhanced Recovery After Surgery(ERAS) Pathway Following Gynecological Oncology Surgery in a Tertiary Level Hospital:A Prospective Randomized Controlled Trial
NA · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · NCT07087366
This study will test whether an ERAS program helps adults with cervical, uterine, or ovarian cancer recover faster and leave hospital sooner after surgery.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 130 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | Female |
| Sponsor | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (other) |
| Locations | 1 site (Dhaka) |
| Trial ID | NCT07087366 on ClinicalTrials.gov |
What this trial studies
This single-center randomized study at a tertiary hospital in Dhaka will compare an ERAS perioperative pathway to conventional care in 160 patients undergoing surgery for cervical, uterine, or ovarian cancer. The ERAS pathway includes coordinated preoperative education and optimization, standardized intraoperative anesthesia and fluid strategies, and structured postoperative protocols to accelerate recovery. Key outcomes include length of hospital stay, postoperative complications, readmissions, same-day discharge rates, and patient satisfaction. Patients will be followed through the immediate postoperative period to capture recovery metrics and adverse events.
Who should consider this trial
Good fit: Adults aged 18–70 years with diagnosed cervical, uterine, or ovarian cancer who are admitted for surgical management and meet the study eligibility criteria.
Not a fit: Patients with severe comorbidities (such as uncontrolled diabetes, chronic respiratory or liver disease), ASA score ≥4, or severe organ dysfunction/failure are excluded and unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, the ERAS program could shorten hospital stays, speed recovery, and reduce postoperative complications and readmissions for patients having gynaecologic cancer surgery.
How similar studies have performed: ERAS pathways have been implemented in colorectal and gynaecologic oncology with prior studies and guidelines reporting reduced length of stay and lower postoperative morbidity.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients between the age of 18-70 years, * diagnosed case with cervical, uterine or ovarian cancer, * Admitted for surgical management . Exclusion Criteria: * Patients with severe comorbidity, including DM,CRD,CLD * patients with American Society of Anesthesiologists risk ≥ 4, * severe organ dysfunction or failure.
Where this trial is running
Dhaka
- Jannat Ferdous — Dhaka, Bangladesh (RECRUITING)
Study contacts
- Principal investigator: JANNAT FERDOUS — Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Study coordinator: DR.Jannatul Ferdous, professor
- Email: jannat@bsmmu.edu.bd
- Phone: 01711607919
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.